Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA clears Orthovita's Vitomatrix dental bone graft substitute

This article was originally published in Clinica

Executive Summary

The US FDA has granted 510(k) clearance for Orthovita's Vitomatrix, a bone graft substitute that can be used in certain dental procedures. This includes operations to fill, augment or reconstruct periodontal or bony defects of the oral and maxillofacial region. The product is a resorbable porous synthetic scaffold that uses the same technology as the firm's Vitos bone graft substitute line. Vitomatrix could be used in around 375,000 procedures per year in the US, Malvern, Pennsylvania-based Orthovita estimates. The firm is currently evaluating potential commercial partners to distribute the product or license the underlying technology.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts